Mark S Singer1, Joanna J Phillips2, Hassan Lemjabbar-Alaoui3, Yang Qing Wang1, Jing Wu4, Radoslav Goldman4, Steven D Rosen5. 1. Department of Anatomy, University of California, San Francisco, CA 94143, United States. 2. Department of Neurological Surgery and Pathology, University of California, San Francisco 94158, United States. 3. Department of Surgery, University of California, San Francisco 94143, United States. 4. Department of Oncology, Georgetown University, Washington, D.C. 20057, United States. 5. Department of Anatomy, University of California, San Francisco, CA 94143, United States. Electronic address: steven.rosen@ucsf.edu.
Abstract
BACKGROUND: SULF2 is an extracellular sulfatase that acts on heparan sulfate proteoglycans and modulates multiple signaling pathways. It is normally bound to the cell surface but can be released into the medium of cultured cells. SULF2 is known to be increased in cirrhotic liver compared to healthy liver. We asked whether SULF2 protein was present in the blood of healthy controls and increased in patients with liver cirrhosis. METHODS: We devised a sandwich ELISA for SULF2 using 2 novel monoclonal antibodies (mAbs) and measured its levels in sera of normal individuals and cirrhosis patients. RESULTS: SULF2 was higher in cirrhosis patients (1460 ± 1160 pg/ml, N=34) than in healthy individuals (728 ± 400 pg/ml, N=37). SULF2 levels increased with age in both healthy and patient groups. CONCLUSIONS: SULF2 may be a useful serologic biomarker for liver cirrhosis.
BACKGROUND:SULF2 is an extracellular sulfatase that acts on heparan sulfate proteoglycans and modulates multiple signaling pathways. It is normally bound to the cell surface but can be released into the medium of cultured cells. SULF2 is known to be increased in cirrhotic liver compared to healthy liver. We asked whether SULF2 protein was present in the blood of healthy controls and increased in patients with liver cirrhosis. METHODS: We devised a sandwich ELISA for SULF2 using 2 novel monoclonal antibodies (mAbs) and measured its levels in sera of normal individuals and cirrhosispatients. RESULTS:SULF2 was higher in cirrhosispatients (1460 ± 1160 pg/ml, N=34) than in healthy individuals (728 ± 400 pg/ml, N=37). SULF2 levels increased with age in both healthy and patient groups. CONCLUSIONS:SULF2 may be a useful serologic biomarker for liver cirrhosis.
Authors: Aliete Langsdorf; Valerie Schumacher; Xiaofeng Shi; Thanh Tran; Joseph Zaia; Sanjay Jain; Mary Taglienti; Jordan A Kreidberg; Alan Fine; Xingbin Ai Journal: Glycobiology Date: 2010-09-20 Impact factor: 4.313
Authors: Anna Wade; Aaron E Robinson; Jane R Engler; Claudia Petritsch; C David James; Joanna J Phillips Journal: FEBS J Date: 2013-02-06 Impact factor: 5.542
Authors: Roman Nawroth; Annemieke van Zante; Sara Cervantes; Michael McManus; Matthias Hebrok; Steven D Rosen Journal: PLoS One Date: 2007-04-25 Impact factor: 3.240
Authors: Ina Kalus; Benedikt Salmen; Christoph Viebahn; Kurt von Figura; Dietmar Schmitz; Rudi D'Hooge; Thomas Dierks Journal: J Cell Mol Med Date: 2009 Nov-Dec Impact factor: 5.310
Authors: Ruby J Siegel; Anil K Singh; Paul M Panipinto; Farheen S Shaikh; Judy Vinh; Sang U Han; H Mark Kenney; Edward M Schwarz; Cynthia S Crowson; Sadik A Khuder; Basil S Khuder; David A Fox; Salahuddin Ahmed Journal: Cell Mol Immunol Date: 2022-09-07 Impact factor: 22.096
Authors: Xin Luo; Nellie A Campbell; Li He; Daniel R O'Brien; Mark S Singer; Hassan Lemjabbar-Alaoui; Keun Soo Ahn; Rory Smoot; Michael S Torbenson; Steven D Rosen; Lewis R Roberts Journal: Hepatology Date: 2021-05-24 Impact factor: 17.298
Authors: Natalie S Lui; Yi-Wei Yang; Annemieke van Zante; Petra Buchanan; David M Jablons; Hassan Lemjabbar-Alaoui Journal: PLoS One Date: 2016-02-16 Impact factor: 3.240
Authors: Sarah A Flowers; Xin Zhou; Jing Wu; Yiwen Wang; Kepher Makambi; Bhaskar V Kallakury; Mark S Singer; Steven D Rosen; Bruce Davidson; Radoslav Goldman Journal: Oncotarget Date: 2016-07-12